Ambrx | protein therapeutics - antibody drug conjugates

A Convergence of Chemistry And Biology To Create Better Medicine

Learn More

WHAT WE BELIEVE

Ambrx is developing innovative protein therapeutics that preserve potency, reduce dosing frequency and improve homogeneity of the drug substance.

Learn More

Our Technology

Ambrx is harnessing the power of an expanded genetic code to optimize the performance of therapeutic proteins, peptides, bi-specifics and full length antibody conjugates

Learn More

PIPELINE

Ambrx has a number of highly differentiated product candidates at various stages of development in its pipeline, with a focus on “best in class” biopharmaceutical product opportunities.

Learn More

Partnerships

Partnerships for Next Generation Biologics

Learn More

News

Feb 23, 2021

SAN DIEGO, Calif., February 23, 2021 – Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create...

A Convergence of Chemistry And Biology To Create Better Medicine

WHAT WE BELIEVE

Our Technology

PIPELINE

Partnerships

News

Ambrx Appoints Audit Executive Chris Nolet to Board of Directors

Ambrx Appoints Gary Yeung as Chief Financial Officer and Chief Operating Officer

FDA Grants ARX788 Fast Track Designation for HER2-positive Metastatic Breast Cancer